NCT06001125View on ClinicalTrials.gov

Methotrexate for Immune Related Arthritis or Arthralgias (IMPACT 2.1)

PHASE2RecruitingINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

August 12, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

November 30, 2029

Conditions

ArthritisArthralgia

Interventions

DRUG

Methotrexate

Methotrexate 20 mg PO weekly

Trial Locations (1)

Unknown

RECRUITING

Cross Cancer Institute, Edmonton

All Listed Sponsors

lead

AHS Cancer Control Alberta

OTHER